534
Participants
Start Date
January 31, 2003
Study Completion Date
July 31, 2004
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
Placebo
The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
Philadelphia
Winston-Salem
Winston-Salem
Miami
Tampa
St. Petersburg
Birmingham
Huntsville
Cincinnati
Indianapolis
Chicago
Kansas City
New Orleans
Dallas
Houston
San Antonio
Austin
Boise
Mesa
Albuquerque
Los Angeles
San Diego
Tacoma
Washington D.C.
Wellesley
Hershey
Warwick
Lead Sponsor
Bayer
INDUSTRY